The FDA has added significant new safety information to the labeling of alosetron hydrochloride (Lotronex, Glaxo Wellcome, Research Triangle Park, NC), a 5-HT3 (serotonin) antagonist indicated for treatment of women with diarrhea-predominant irritable bowel syndrome. The updated labeling highlights information about potentially serious complications of constipation and the risk of ischemic colitis, and specifies that the product is intended for women who have had symptoms that are not attributable to organic disease for at least 3 months.
Henney JE. Important Warning About Alosetron Hydrochloride. JAMA. 2000;284(13):1640. doi:10.1001/jama.284.13.1640
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: